First-in-human study of SNA-125.
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs CT 340 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- 09 Nov 2017 According to a Sienna Biopharmaceuticals media release, company is planning to initiate the study within the first half of 2018.
- 20 May 2013 New trial record
- 10 May 2013 First-in-human studies of CT 340 are expected to commence in 2013, according to a Creabilis media release.